Vaxcyte, Inc.
PCVX
Rangering i aksjer
#2080
Vaxcyte, Inc. is a biotechnology firm in the clinical development stage,... Vaxcyte, Inc. is a biotechnology firm in the clinical development stage, dedicated to creating innovative protein-based vaccines. Its primary objective is to either prevent or manage bacterial infectious diseases. The company's leading vaccine candidate is VAX-24, an experimental 24-valent pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials, intended to address invasive pneumococcal disease and pneumonia. Beyond its flagship candidate, Vaxcyte is also advancing several other vaccine programs: VAX-XP, designed to offer protection against emergent bacterial strains and counter antimicrobial resistance; VAX-A1, a conjugate vaccine formulation aimed at Group A Streptococcus; and VAX-PG, a novel protein vaccine specifically developed to target the key pathogen responsible for periodontitis. The organization, which was initially established as SutroVax, Inc., officially rebranded as Vaxcyte, Inc. in May 2020. Founded in 2013, its corporate headquarters are situated in San Carlos, California.
Aksjekurs
$64.29
Sist synkronisert: 2026-10-19
Markedsverdi
$9.86B
Endring (1 dag)
1.05%
Endring (1 år)
49.86%
Land
US
Handel Vaxcyte, Inc. (PCVX)
Kategori
Healthcare
Historikk for aksjesplitt for Vaxcyte, Inc. (PCVX)
Aksjen Vaxcyte, Inc. (symbol: PCVX) har gjennomgått totalt 0 aksjesplitt.
Den nyeste splittelsen skjedde Oct 20, 2026.
Én PCVX-aksje kjøpt før Oct 20, 2026 tilsvarer i dag 0 PCVX-aksjer.
Den nyeste splittelsen skjedde Oct 20, 2026.
Én PCVX-aksje kjøpt før Oct 20, 2026 tilsvarer i dag 0 PCVX-aksjer.
Liste over aksjesplitt
| År | Splitt | Multiplikator | Kumulativ multiplikator |
|---|---|---|---|
| Ikke nok data for de angitte datoene. | |||
Aksjesplitt for lignende selskaper eller konkurrenter
| Selskap | Antall aksjesplitt | Kumulativ multiplikator | Land |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
CH
|
|
| 0 | - |
NL
|
